Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus EVZIO AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus EVZIO AUTOINJECTOR.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs EVZIO (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
None Documented
None Documented
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist